Compare · NAMS vs NVO
NAMS vs NVO
Side-by-side comparison of NewAmsterdam Pharma Company N.V. (NAMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 70.5x NAMS ($2.46B).
- Over the past year, NAMS is down 45.5% and NVO is down 28.6% - NVO leads by 16.9 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 15 for NAMS).
- Company
- NewAmsterdam Pharma Company N.V.
- Novo Nordisk A/S
- Price
- $19.84-3.76%
- $38.82-1.05%
- Market cap
- $2.46B
- $173.66B
- 1M return
- -9.51%
- -10.14%
- 1Y return
- -45.48%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NAMS
- Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 50,246 units of Ordinary Shares and sold $1,257,657 worth of Ordinary Shares (50,246 units at $25.03) as part of a pre-agreed trading plan (SEC Form 4)
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Other Events
- Chief Executive Officer Davidson Michael H. bought $226,500 worth of Ordinary Shares (10,000 units at $22.65), increasing direct ownership by 1% to 792,923 units (SEC Form 4)
- Director Smither John W sold $40,512 worth of Ordinary Shares (1,600 units at $25.32), decreasing direct ownership by 15% to 8,760 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by NewAmsterdam Pharma Company N.V.
- Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 125,000 units of Ordinary Shares and sold $3,363,750 worth of Ordinary Shares (125,000 units at $26.91) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank